At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...
ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
Investing.com - Barclays has maintained its Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a price target of $44.00, representing nearly 79% upside from the current price of $24.61.
ATLANTA, GA, UNITED STATES, January 13, 2026 / EINPresswire.com / — Enlighten Clinical Solutions today announced the official release of its integrated electronic Trial Master File (eTMF) module, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results